Acidic fibroblast growth factor (aFGF) is a potent mitogenic and chemotactic agent for vascular endothelial cells, dermal fibroblasts, and epidermal keratinocytes, the principal cellular constituents of skin. To explore its potential to heal chronic dermal wounds, we applied pure recombinant human aFGF topically to full-thickness excisional injuries in healing-impaired genetically diabetic mice. Transformation of the nonlinear percent initial wound areas as a function of time to linear rates of tissue ingrowth from the original wound edges showed that aFGF increased wound closure in a dose-dependent manner. Optimal 3-lLg/cm 2 doses of aFGF nearly tripled G rowth factors that are mitogenic or chemotactic or that promote the difFerentiation of one or more types of cells that participate in the repair of injured skin could, in principle, promote cutaneous healing. The fibroblast growth wctors (FGFs) are a fami ly of nine known homologo us mitogens [1] [2] [3] that stimulate cells of mesodermal and ectodermal origin through at least four unique membrane-spanning tyrosine kinase receptors and their alternatively transcribed variants [4, 5] . Acidic FGF (aFGF or FGF-1) appears to be unique among the characterized FGFs in its ability to bind all known FGF receptors with high affmity [5] . This broad receptor specifi city presumably' contributes to its multiple cellular targets ill vitro and diverse therapeutically relevant biologic activities in animal models of tissue repair [6] . Pure aFGF is a potent mitogen for dermal fibroblasts [7, 8] , vascular endothelial cells [9] , and e piderm al keratinocytes (7, 10] , the principal ceUs in skin. In addition, aFGF is ch emotactic for vascular endothelial cells ill. IIitro
Acidic fibroblast growth factor (aFGF) is a potent mitogenic and chemotactic agent for vascular endothelial cells, dermal fibroblasts, and epidermal keratinocytes, the principal cellular constituents of skin. To explore its potential to heal chronic dermal wounds, we applied pure recombinant human aFGF topically to full-thickness excisional injuries in healing-impaired genetically diabetic mice. Transformation of the nonlinear percent initial wound areas as a function of time to linear rates of tissue ingrowth from the original wound edges showed that aFGF increased wound closure in a dose-dependent manner. Optimal 3-lLg/cm 2 doses of aFGF nearly tripled G rowth factors that are mitogenic or chemotactic or that promote the difFerentiation of one or more types of cells that participate in the repair of injured skin could, in principle, promote cutaneous healing. The fibroblast growth wctors (FGFs) are a fami ly of nine known homologo us mitogens [1] [2] [3] that stimulate cells of mesodermal and ectodermal origin through at least four unique membrane-spanning tyrosine kinase receptors and their alternatively transcribed variants [4, 5] . Acidic FGF (aFGF or FGF-1) appears to be unique among the characterized FGFs in its ability to bind all known FGF receptors with high affmity [5] . This broad receptor specifi city presumably' contributes to its multiple cellular targets ill vitro and diverse therapeutically relevant biologic activities in animal models of tissue repair [6] . Pure aFGF is a potent mitogen for dermal fibroblasts [7, 8] , vascular endothelial cells [9] , and e piderm al keratinocytes (7, 10] , the principal ceUs in skin. In addition, aFGF is ch emotactic for vascular endothelial cells ill. IIitro [11] and induces n ew blood vessel growth ill IIillo [9, 12] . We previously reported that aFGF accelerates the rate of healing of fuU-thickness dermal wounds in nonn al healthy rod ents as reflected by en hanced gran ulation ti ss ue deposition , vascularization, epidermal g rowth, and closure [13] .
Chronic non-healing dermal ulcers are a serious problem in diabetic patients. The mutant C57BL/Ks-db/db diabetic mouse has emerged as a potentially re levant healing-inlpaired model for studying the effects of cutaneo us wound-healing agents. These homozygous genetically diabetic mice develop obesity aJld hyperManuscript received October 27, 1994 ; final revision received February 10, 1995; accepted for publication February 20, 1995. Reprint requests to: Dr. Kenneth A. Thomas glycemia that is resistant to insulin, analogous to humaJl type II di abetes [14] . They also show signs of diabetes 'such as excessive drinking and urination and greatly elevated urinary glucose levels. Wounds in these mice exhibit a marked delay in cellular infiltration, granulation tissue fonnation, and wound closure [15] [16] [17] [18] [19] [20] [21] [22] . Previous studies have used this model to evaluate formulations of aFGF [21, 22] . In this report, we show that recombinant human aFGF markedly accelerates the rate of healing of fuU-thickness excisional dermal wounds in diabetic mice aJld describ e the histology of th e response. We also originally demonstrate that the rate of tissue ingrowth from wound margins in this model of impaired healing is constant with time, providing an objective m eas ure of linear healing kinetics. In addition, aFGF is shown to accelerate the rate ofLinear ingrowth and substantially decrease the .time required to achieve tota l closure .
MATEIUALS AND METHODS
Growth Factors Human recombinant aFGF was prepared as described [23 ] . Briefly, a synthetic gene encoding the 140 amino acid protein was expressed in Escherichia coli, and the recombin ant product was purified chromatographically to apparent homogencity. Pure aFGF was formulated in phosphate-buffered salinc (PBS) with a threefold ma ss excess of porcine hepari n (Sigma), which binds and stabilizes the protcin. The mitogcnic activity of aFGF was measured by full dose-rcsponse DNA-synthesis assays using Balbi c 3 T3 fibroblasts [24] .
Skin Organ Culture Full-thickness shaved skin biopsy specimens 6 mm in diameter, removed from diabetic mi ce at wounding, were p laced in organ culture as described [13] . Briefly, tissue samples were incubated at 37°C in Du lbecco's modifi ed Eagle's medium (Gibco) supplemented with 0.25%
heat-inactivated bovin e serum (Gibco) and 50 /Lg/m 1 heparin. The skin specimens were treated daily for either 2 or 3 d with 0,1,10, and 100 /Lg/ml aFGF . They were then labeled for 24 h with 4 /LCi of[lIIethl'/-' Hlthymidine (20 Ci/mm ol; New England Nuclear). After thymidine labeling, the specim ens were washed, solubil. ized, and counted as described [13] . 
850
Animals Fem ale Cs7BLlKs-db/ db diabetic mice , 11 weeks old, were obtained from Jackson Laboratories (Bar Harbor, ME) . T he nuce were housed in steril e microisolator boxes (four per box) with sterile water and bedding and were kept in a semi-barrier quarantine facili ty. Supplemental heat was provided w ith electric heating pads under half of each box after wounding to prevent hypoth ermia and reduce mortali ty. Wound-Closure Modcl Mice were anesthetized with intraperitoneal inj ections of 110 mg kctam in e and 9 mg xylazine per kg of body weight. T he mid-back and thoracic skin was shaved and disinfected with a 2% Chlo rhexidine surgical scrub (N olvasan ; Aveco, Ft. Dodge, IA) followed by 70% ethanol. A template 1.6 cm in diameter was used to mark a 2.0-cm 2 circlc o n the mid-dorsa l area, and a single full-thi ckness wound was created by blunt excisio n w ith sterile curved ir is scissors. Wound areas typically in creascd to approximately 2.3 cm 2 soon after inju ry, presumably beca use of con traction of the dermis along the wound perimeter. All surgical and subseq uen t healing analysis procedures were performed in a laminar flow hood usin g full aseptic techniqu es. Filter-sterilized growth factors and correspondin g vehiclc con trol solutions were applied topically. Doses (28 JLI) w ere administe red after injury (day 0) and 3 and 7 d later. The wounds were covered with a sem itransparent Bioclusive dressing Oo lmson & jolmson Produ cts , N ew Brunswick, NJ) for protection, maintenance of a moist environ ment, and prevention of crust fonnation . Wound fluid samples werc taken at day 10 after injury and cultured for aerobic and ana erobic microorganisms. Animals from wluch cultures exhibited more than 50 colonies per wound were excl udcd from the study analysis. Prevention of even mild or subcluucal in fectio n resulted in a consistent m axima l hca ling impairment, thus providing a large wound-healing WU1-dow for eva luation of treatment effects.
Hcaling Analysis Wound appearan ces were reco rded ph otographically, and th e ir perim cters wcre traced onto stcrile glass slides applied directly to thc exposed wound surf.1ces after prewetting with a drop of sterile physiologic sa line . Meas urements were made immediately after wounding and twice weekly thereafter until the wounds were comple tely closed. Wound areas and perimeters were determined fro m the glass-s lide tracings using compu te rized image anal ysis (Presage C V-6; Advanced Imaging Concepts, Prin ceton, NJ). Statistical signific'mces of differences between gro ups were evaluated using an unpaired two-tail ed Student t test.
Hea ling expressed as a decrease in percent uutial area was convertcd to lin ear ingrowth from thc wound edges by dividing the difference in wound areas by the average wound perimeters at seq ucntial time in tervals. Tota l ingrowth at a specific time is the sum of the in cremental ingrowth distan ces up until tha t ti me. T hi s transformation linearized closure as a fun ction of time, thereby all owing express ion of healing as kinetic rates that were constan t over time. A similar analysis, independently proposed by H opkins and J ami eso n [25J and latcr modified by Gilm an [26] , ha s been used to determine the lin ear rate of healing of diabetic and veno us stasis leg ulcers [25, 27, 28] . Slopes of linear healing curves for individu al a1umals were determined by regression ana lysis and analyzed statistically USUlg an lll1-paired two-tailed Student t test.
Wounds, examined twice weekly to mOlutor time to tota l closure, were considered fully hea led w hen moist granul ation tissue was no longer apparent, indicating a functional ep idennal water-permeabili ty barrier . C losure was al so confirmed lustologicall y. Time-point comparisons of the fraction of hea led "e,.slIs unhea led wounds were an alyzed by tlle K statistic with Yates correction, and group comparisons of absolute days to total closure for individual animals were ana lyzed by an unpaired two-tailed Studen t t test.
Histologic Analysis After sacrifice by CO 2 inhalation, the mice were eviscerated and fixed ovenught in 10% Z n forma lin (Anatech, Battle C reek , MI) . Wound tiss ue was removed Witll adjacent unwounded skin and underlying fasc ia and muscle. T he backbone wa s included to stabilize the wound tissue and maintain n ormal geometry for later histomorphometric measurements. T he tissue was decalcified ovenug ht in Ca l-EXlI (Fischer Scientific, Orangeburg, NY) and bisected through tllC center. T he halves were then cmbedded in paraffin, and s-JLm-tlUck sections were cut. Central sections through tile wound were deparaffini zed, cleared, rehydrated, and stain ed with Masson trichrom e.
Morphometri c anal yses of represcntative mid-wound lustologic sections were donc using a Presage CV-6 image analyzer. Images were captured w ith a color video camera mounted on a mi croscope and displayed on a high-resolu tion mon itor. Granulatio n tisme zones in th e wound bed, identifIed by the abunda nt bl ood vessels between the edges of unwounded dermal tissue, were traced using a digita l drawing board. Unwounded demlis was identified by its characteristic highly organized collagen fibril staining. Wound contraction was assessed by measuring the distance between these un wou nded margins at a l11id-dermal level. T he lengtl1S and cross-sectional areas of new epidermis werc also measured.
RESULTS
aFGF Induces DNA Synthesis in Skin Organ Cultures Diabetic mouse 6-mm full-thickn ess skin biopsy specimens incorporated [lIl cthyl-3H]thymidine in response to daily aFGF doses of 0, 1, 10, and 100 /-Lg/ ml, with a clear response peak seen at 10 /-Lg/ ml (Fig 1) . T h erefore, cells withi n the skin responded mitogenically to aFGF as a function of dose . The highest concentration of aFGF resulte d in suboptimal incorpora tion of radiolabel, an effect noted earlier in normal rodent skin [13] and in monolayer cell cultures [23] . P lugs re m ained viable for 4 d, after which they deteriorated b oth in ability to incorporate t h ymidine and in structural integrity.
aFGF Accelerates Wound Closure in Diabetic Mice Fullthickness d e nnal excisiona! wounds 1.6 cm in diameter closed substa nti a lly faster in response to three doses of 3 /-Lg aFGF per cm 2 initial wound area administered during the first week after wou.nding compared with treatment with the corresponding vehicle con tro l (Fig 2a) . Statistica.ll y significant enhan cements of the healing rate (p :5 0.01) of aFGF-treated wounds were seen as early as day 7 after injury an d continu e d throughout the test period. A 50% m aximum difference in p e rce nt of initial area b etween aFGf.· and vehicl e-treated wounds occurred from 10 to 14 d after injury. T hi s difference c orresponded to a 12-fold decrease in wound size in aFGF-treated mice at d ay 14 compared with those receiving the correspond.ing PBS / heparin vehicle. A ltho u g h wounds receiving a liquid vehicle h ealed som ewhat faster than wounds receiving n othing, treatment with e ither PBS or normal saline resulted in h ealing rates equival ent to those with the h eparin-containing PBS vehicle (data n ot sh own).
As shown in Fig 2a, Time (days) Figure 3 . Enhancement of Wound Healing by aFGF is Dose Dependent Three topical applica tions of aFGF, ranging from 0.1 to 10 J.Lg/cm 2 per '')se, applied during the first w eek after injury res ulted in si gnifi can , dose-related increases in healin g rates over paired vehi cle controls (Fig 4a) . T he 0.001-J.Lg/cm 2 (not shown) and 0.01-J.Lg/cm 2 do ses were ineffective, thus establishing a "no effect" level between 0.01 and 0.1 J.Lg/ cm A dose-response relation was also seen in the time to comple te wound closure (Fig 4b) . Application of aFGF from 0.1 to 10 J.Lg/ cm 2 per dose significantly redu ced th e tim e req uired for these wounds to close completely. In the dose range of 0.6 to 3. of aFGF, wounds showed a visible redd e ning and leakage of serous fluid, possi bly du e to capillary leakage associated with n eovascularizatio n. By day 5, th ese characteristics were even more pronounced. Wounds receiving o nly vehicle contained little or no visible serous fluid and substantially less ap pare nt n eoangiogenesis.
As observed previously in norm al rodent wounds [13] , histologic m eas ure m ent of the widths of the diab etic wounds between the edges of the uninjured dermis indicated that aFGF did not alter wound contraction (data not shown). Histomorphometric evaluation of th e wounds de monstrated that a.!though aFGF had only a modest effect o n the growth of n ew e pide mlis (Fig 6a,b) at 5 dafter injury, it stimulated a 19-fold increase in granulation tissue crosssectional area (p :::; 0.05; Fig 6c) . By day 10 after injury, a three-to fourfold improve m ent was o bserved in reepithelializa tion (p oS 0.01) , w ith greater than a fourfo ld increase in g ranulation tissue formation (p :::; 0.01). At day 15, granulation tissue area of aFGF-treated mice was less than twofold larger than that in ve hicle-treated mice . Tllis diminish ed difference co uld be du e to tissue re mod eling associated with maturation of the aFGF-indu ced a ->- granulation tissue in largely closed wounds. In contrast, by day 15 epithelial area and length were increased four-to sixfold (p :5 0.05) by aFGF treatment. Therefore, the increased closure that occurred by day 15 in aFGF-treated wounds could have been the consequence of deposition and maturation of granulation tissue, which facilitated subsequent coverage by epithelium. Epidermal and dermal thickness in addition to dermal collagen fibril maturation and organization of fully healed vehicle-and aFGF-treated wounds were virtually indistinguishable by gross histology. Therefore, despite substantially accelerated healing, aFGF promoted a morphologically normal tissue-repair response.
DISCUSSION
Skin organ cu1ture studies with radiolabeled thymidine clearly showed that aFGF is capable of stimulating DNA synthesis in the skin of db! db mice. Tllis result was comparable to the response that we had seen previously in nonnal rodent skin [13] and suggests that aFGF might promote dermal healing in these animals. Indeed, we found that aFGF substantially accelerated the closure of fullt1lickness excisional wounds in healing-impaired diabetic nUce. A maximal twofold decrease in wound area was seen previously in aFGF-treated nomlal mice compared with vehicle-treated controls [13] , whereas in the present study, a 12-fold improvement was seen in the diabetic mice at 2 weeks after injury. Therefore, the efficacy of aFGF appears greater in healing-impaired alUmals, perhaps in part as a result of t11eir slower spontaneous healing. The commonly used nonlinear measure of wound closurereduction in percent initial open wound area-decreased rapidly during the early phases of healing but slowed as the wounds approached closure, giving the impression t11at aFGF is most active in the initial stages of healing. However, transfonned to tissue ingrowth from the wound edges, healing was seen to proceed at a constant rate throughout closure, independent of the size of the wound. Evaluation of healing as a function of dose using this method demonstrated that an optimal 3 f.Lg! cm 2 of aFGF promoted nearly a threefold increase in the rate of linear closure, with a correspondillg approximate threefold decrease in the time to total closure.
Topical application of aFGF resulted in a substantial enhancement of granulation tissue formation , followed by migration of epidemlis to acllieve significantly earlier total closure. Near closure, granulation tissue cross-sectional area decreased, presumably because of remodeling associated with maturation. Evaluation of fully closed vellicle-control-and aFGF-treated wounds indicated no significant difference in epidermal or demlal t1lickness or in dermal Day 15 collagen fibril maturation and organization. Therefore , aFGF treatm ent led to healed tissue that appeared histologically normal. The efficacy of aFGF is mediated through one or more transm embrane tyrosine kinase FGF receptors (FGFRs). Mitogenic responses to FGFs are attributable to four known receptors (FGFR1 through FGI'R4) , the first three of which are subj ect to alternative transcription of exon In encoding the C-tenni.nal half of the extracellular immunoglobulin ligand-binding domain proximal' to thc membrane. Alternative ly spliced exon IITb forms, all preferentially expressed in skin, retain their tight bindulg to aFGI' but bind basic I'GF (bI'GI') with either substantially lower affinity or not at all [5,29-3 1) . The alternatively transcribed exon IIIb version of I'GI'R2, but not I'GFR3, also binds keratinocyte growth factor (KGF or FGI'-7) with high affinity and is the predominant fonn of I'GI'R2 in diabetic mouse skin [32] . Its expression by epidermal THE JOURNAL OF INVESTIGATIVE DERMATOLOGY keratinocytes could account for their greater mitogenic responsiveness to aFGF as compared with bFGI' [8] . Selective epidermal expression of a dominant-negative truncated form of tlus receptor resulted Ul epidermal atrophy, a decreased number of hair follicles, and compromised wound reepithelialization in transgenic mice [33] .
In contrast, the widely distributed, alternatively transcribed forms ofFGFR1 and FGFR2 incorporating exon lIIc, expressed on fibroblasts and vascular endothelial cells, bUld aFGF and bFGF with similar affinities, as reflected by their comparable l1utogenic potencies on these cells, but do not recogJuze KGF. Epidennal expression ' of truncated dommant-negative I'GFR1-IIlc, wluch can fonn nonfunctional heterodimers with several different full-length FGFRs, resulted in aberrant keratinocyte differentiation and keratul expression in transgenic nUce [34] . Because KGI' does not bind to the IIIc fonn of this receptor, other epidermally expressed FGFs such as aFGI' released by keratinocyte death might also normally function in the epidennis. Therefore, exogenous aFGI', wluch binds with high affinity to both the exon IlIb and IIIc fonns of FGFRs, should be uniquely able to supplement the activities of not only endogenous aFGF but also bFGF and KGF .
As in diabetic humans, the etiology of the healulg unpairment Ul diabetic mice is not entirely clear. The expression of FGF and FGFR mRNAs has been characterized Ul response to fuU-thickness excisional skin wounds in normal [35] and diabetic [32] mice. In nornlal animals, aFGF and bFGF mRNAs increased 10-and fourfold, respectively, within 1-5 d of wounding and returned to nonnal low levels within 1 week of injury. In contrast, expression of KGF mRNA increased 160-fold witllin 1 d of inju ry and remained approximately 100-fold elevated 1 week later. KGF mRNA expression was localized witllin the d emus, whereas KGF receptor (FGFR2-IIIb) mRNA was selectively expressed Ul the KGF-responsive epidermis. In excisional wounds of healing-unpaired db/db diabetic mice, KGF mRNA peak expression is enhanced only five-to tenfold and is delayed 2-4 d. Furthermore, ul creased expression ofaFGF and bFGF in db/db wOlUlds was also found to be short-Lived, and FGFR mRNA leve ls declined throughout the first week after injury . Thus, diminished FGF function could contribute to impaired healing in the db/db mouse and might help explai1l the efficacy of exogenous aFGF.
In addition to decreased ulduction of endogenous FGFs and , perhaps, other growth factors, the impaired healing could be related to delayed migration of inflammatory ceUs and fibroblasts into the wound as a consequence of suppressed immune function Ul these mice [16,18 ,36] . These mi ce are reported to have an abnormally small spleen and thymus as weU as elevated levels of plasma corti costerone [18, 37) , wluch might delay healing in a manner similar to that of unmunosuppressive glucocorticoids [19, 37] . Immunosuppression might also facilitate ulfections that could lead to the inconsistent healing responses reported in velucle control wounds in earlier aFGF studies [21, 22] . We have observed that such infections can ca use erratic acceleration of wound closure, possibly by stimulating ceUular infiltration of immune cells. Bacteria-enhanced healing of normal rat incisional wounds has been reported recently. * Although not clinically desirable, infectioninduced heawlg could be secondary to the general inflammatoryresponse-mediated release of a variety of stimulatory cytokines, including some known to promote angiogenesis.
Although wounding and dOSUlg protocol differences prevent direct comparison with aFGI', unprovements in healing have also been seen in response to other growth factors in the db/db mouse. Topical doses ofbFGF were reported to promote excisiona! wound healing [16, 20] . Between 12 and 18 d after injury, hFGF-induced granulation tissue t1uckness decreased and matrix density ulcreased [15] , suggesting tissue remodeling and maturation similar to that which we observed in these studies. Human recombinant platelet- derived growth factor-BB has also been reported to be an active healing agent in the db/db model [16, 17] . Although a single topical dose of platelet-derived growth factor-BB was ineffective, five consecutive daily doses resulted in a significant improvement in closure rate at day 21. Both mitogens also have been shown to reverse the healing impairment in protein-malnourished db/db diabetic mice [38] , a pertinent observation given that malnutrition can also compromise tissue repair in humans. However, no reports are avaiJable on the effects of either bFGF or platelet-derived growth factor on the clinicalJy relevant parameter of time to total wound closure.
The impairment in healing of full-thickness wounds in diabetic mice is a reproducible and potentially important model for determining growth factor clinical efficacy. Human aFGF has been demonstrated to accelerate full-thickness excisiona! wound repa.ir and to shorten the time to complete closure in tills model. Thus, aFGF has potential therapeutic applications for the cl.in.ical treatment of ChrOlllC non-healing dermal ulcers resulting from conditions, such as diabetes, that impair nonnal healing.
